Trades on 1 secondary market
Elegen
Elegen is a synthetic biology company founded in 2017 and headquartered in Menlo Park, California that manufactures high-accuracy synthetic DNA through its proprietary cell-free ENFINIA platform. Rather than relying on traditional cell-based cloning, ENFINIA combines microfluidics, artificial intell
Elegen is an API provider whose private shares are listed on 1 secondary market: EquityZen.
Where It Trades
Listing data is compiled from the public marketplace pages of Forge Global, Hiive, EquityZen, Nasdaq Private Market, and Augment. A listing indicates that a venue has published a page for this company — it is not an offer, a quote, or investment advice, and APIs.io has no affiliation with any venue.